# Medical Oncology Coverage

## Breast
- DCIS
- Invasive

## Skin
- Melanoma
  - Brain Metastasis
  - Ocular

## Gastrointestinal
- Anal
- Colon
- Rectal
- Gastric
- Esophageal
- GE Junction
- Pancreatic

## Genitourinary
- Bladder
- Prostate
  - Adenocarcinoma
  - Small Cell
- Renal Cell
- Testicular
  - Seminoma
  - Non-seminoma
  - Sex cord stromal tumors

## Hematologic
- ITP
- CML
- MDS
- Multiple Myeloma
- Lymphomas:
  - Hodgkin's
  - Classic
  - Lymphocyte Predominant
  - Non-Hodgkin's
  - CLL
  - SLL
  - Diffuse Large B Cell
  - Follicular
  - High Grade
  - Mantle Cell
  - Marginal Zone
  - Mediastinal Large B Cell
  - Peripheral T Cell
  - Waldenstrom's/
    Lymphoplasmacytic

## Gynecologic
- Ovarian
- Uterine
  - Endometrioid Histology
  - Carcinosarcomas
  - Papillary Serous & Clear Cell Histology
  - Low Grade Endometrial Stromal Sarcoma
  - High Grade
    Undifferentiated/
    Leiomyosarcoma

## Head & Neck
- Hypopharynx
- Larynx
- Nasopharyngeal
- Occult Primary
- Oral Cavity
- Oropharynx
- Other Sites

## Thoracic
- Mesothelioma
- NSCLC
- SCLC

## CNS
- Neuro-onc
## Medical Oncology: On Pathway Rates

Data for all customers (excluding Private Label centers)
Medical Oncology
12 months ended 11/30/16

<table>
<thead>
<tr>
<th>Disease</th>
<th>On-Pathway Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bladder</td>
<td>76.0%</td>
</tr>
<tr>
<td>Breast</td>
<td>87.0%</td>
</tr>
<tr>
<td>CML</td>
<td>76.3%</td>
</tr>
<tr>
<td>Colorectal</td>
<td>83.1%</td>
</tr>
<tr>
<td>Gastroesophageal</td>
<td>73.1%</td>
</tr>
<tr>
<td>Head and Neck</td>
<td>83.2%</td>
</tr>
<tr>
<td>Lymphoma and CLL</td>
<td>77.6%</td>
</tr>
<tr>
<td>MDS</td>
<td>85.8%</td>
</tr>
<tr>
<td>Melanoma</td>
<td>86.3%</td>
</tr>
<tr>
<td>Mesothelioma</td>
<td>59.2%</td>
</tr>
<tr>
<td>Multiple Myeloma</td>
<td>78.4%</td>
</tr>
<tr>
<td>Non-Small Cell Lung</td>
<td>79.1%</td>
</tr>
<tr>
<td>Ovarian</td>
<td>68.4%</td>
</tr>
<tr>
<td>Pancreatic</td>
<td>85.3%</td>
</tr>
<tr>
<td>Prostate</td>
<td>86.4%</td>
</tr>
<tr>
<td>Renal Cell</td>
<td>81.8%</td>
</tr>
<tr>
<td>Small Cell Lung</td>
<td>81.4%</td>
</tr>
<tr>
<td>Testicular</td>
<td>92.0%</td>
</tr>
<tr>
<td>Thyroid</td>
<td>82.4%</td>
</tr>
<tr>
<td>Uterine</td>
<td>76.9%</td>
</tr>
<tr>
<td><strong>MedOnc Total</strong></td>
<td><strong>82.2%</strong></td>
</tr>
</tbody>
</table>